Tocilizumab Improved both Clinical and Laboratory Manifestations Except for Interleukin-18 in a Case of Multiple Drug-Resistant Adult-Onset Still's Disease

Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab

(2010) Keiichi Sumida et al.   CLINICAL RHEUMATOLOGY

Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome

(2010) Masafumi Kobayashi et al.   Modern Rheumatology

Successful tocilizumab treatment in a patient with adult-onset Still’s disease complicated by chronic active hepatitis B and amyloid A amyloidosis

(2010) Dai Kishida et al.   Modern Rheumatology

Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab

(2009) Kazuko Matsumoto et al.   CLINICAL RHEUMATOLOGY

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production

(2008) Yasushi Uchiyama et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

(2008) Hideko Nakahara et al.   Modern Rheumatology